# Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

> **NCT01967888** · PHASE2,PHASE3 · COMPLETED · sponsor: **Dompé Farmaceutici S.p.A** · enrollment: 104 (actual)

## Conditions studied

- Pancreatectomy for Chronic Pancreatitis

## Interventions

- **DRUG:** Reparixin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01967888
- **Lead sponsor:** Dompé Farmaceutici S.p.A
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2018-01
- **Final completion:** 2018-01
- **Target enrollment:** 104 (ACTUAL)
- **Last updated:** 2023-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01967888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01967888, "Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01967888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*